Ming Ji

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7531043/publications.pdf

Version: 2024-02-01

33	787	623734	526287
papers	citations	14 h-index	27 g-index

34	34	34	1195
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	YTHDF1 Promotes Gastric Carcinogenesis by Controlling Translation of FZD7. Cancer Research, 2021, 81, 2651-2665.	0.9	150
2	Chlorogenic acid inhibits glioblastoma growth through repolarizating macrophage from M2 to M1 phenotype. Scientific Reports, 2017, 7, 39011.	3.3	108
3	Drug-free mannosylated liposomes inhibit tumor growth by promoting the polarization of tumor-associated macrophages . International Journal of Nanomedicine, 2019, Volume 14, 3203-3220.	6.7	59
4	Targeted delivery of chlorogenic acid by mannosylated liposomes to effectively promote the polarization of TAMs for the treatment of glioblastoma. Bioactive Materials, 2020, 5, 694-708.	15.6	57
5	Myostatin induces p300 degradation to silence cyclin D1 expression through the PI3K/PTEN/Akt pathway. Cellular Signalling, 2008, 20, 1452-1458.	3.6	41
6	Evaluation of inhibitory effects of flavonoids on breast cancer resistance protein (BCRP): From library screening to biological evaluation to structure-activity relationship. Toxicology in Vitro, 2019, 61, 104642.	2.4	41
7	Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-Kinase Inhibitors for Cancer Treatment. Journal of Medicinal Chemistry, 2018, 61, 6087-6109.	6.4	30
8	CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway. Cancer Letters, 2016, 381, 391-403.	7.2	25
9	Bt354 as a new STAT3 signaling pathway inhibitor against triple negative breast cancer. Journal of Drug Targeting, 2018, 26, 920-930.	4.4	22
10	Azacyclo-indoles and Phenolics from the Flowers of Juglans regia. Journal of Natural Products, 2017, 80, 2189-2198.	3.0	20
11	Validating a Selective S1P₁ Receptor Modulator Syl930 for Psoriasis Treatment. Biological and Pharmaceutical Bulletin, 2018, 41, 592-596.	1.4	19
12	LBâ€1 Exerts Antitumor Activity in Pancreatic Cancer by Inhibiting HIFâ€1Î± and Stat3 Signaling. Journal of Cellular Physiology, 2015, 230, 2212-2223.	4.1	18
13	A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models. Acta Pharmaceutica Sinica B, 2020, 10, 276-288.	12.0	18
14	Oral SMEDDS promotes lymphatic transport and mesenteric lymph nodes target of chlorogenic acid for effective T-cell antitumor immunity. , 2021, 9, e002753.		18
15	Chaperone-mediated autophagy degradation of IGF-1RÎ² induced by NVP-AUY922 in pancreatic cancer. Cellular and Molecular Life Sciences, 2019, 76, 3433-3447.	5.4	15
16	LXY6090 – a novel manassantin A derivative – limits breast cancer growth through hypoxia-inducible factor-1 inhibition. OncoTargets and Therapy, 2016, Volume 9, 3829-3840.	2.0	14
17	Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer. Biochemical Pharmacology, 2016, 107, 29-40.	4.4	14
18	CAT₃, a prodrug of 13a(S)-3-hydroxyl-6,7-dimethoxyphenanthro[9,10-b]-indolizidine, circumvents temozolomide-resistant glioblastoma via the Hedgehog signaling pathway, independently of O⁶-methylguanine DNA methyltransferase expression. OncoTargets and Therapy, 2018, Volume 11, 3671-3684.	2.0	14

#	Article	IF	Citations
19	A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity. Cancer Letters, 2020, 495, 22-32.	7.2	12
20	Discovery of new thieno[2,3-d]pyrimidine and thiazolo[5,4-d]pyrimidine derivatives as orally active phosphoinositide 3-kinase inhibitors. Bioorganic and Medicinal Chemistry, 2021, 29, 115890.	3.0	12
21	Sphingosine-1-Phosphate Receptor Subtype 1 (S1P1) Modulator IMMH001 Regulates Adjuvant- and Collagen-Induced Arthritis. Frontiers in Pharmacology, 2019, 10, 1085.	3.5	10
22	Secreted HSP90Î±-LRP1 Signaling Promotes Tumor Metastasis and Chemoresistance in Pancreatic Cancer. International Journal of Molecular Sciences, 2022, 23, 5532.	4.1	10
23	Structureâ€“Activity Study of Nitazoxanide Derivatives as Novel STAT3 Pathway Inhibitors. ACS Medicinal Chemistry Letters, 2021, 12, 696-703.	2.8	9
24	Discovery of Quinazoline-2,4(1H,3H)-dione Derivatives Containing 3-Substituted Piperizines as Potent PARP-1/2 Inhibitorsâ”€Design, Synthesis, In Vivo Antitumor Activity, and X-ray Crystal Structure Analysis. Journal of Medicinal Chemistry, 2021, 64, 16711-16730.	6.4	9
25	Discovery of Benzocyclic Sulfone Derivatives as Potent CXCR2 Antagonists for Cancer Immunotherapy. Journal of Medicinal Chemistry, 2021, 64, 16626-16640.	6.4	8
26	A novel PI3K inhibitor XH30 suppresses orthotopic glioblastoma and brain metastasis in mice models. Acta Pharmaceutica Sinica B, 2022, 12, 774-786.	12.0	7
27	A Dual PI3K/HDAC Inhibitor Downregulates Oncogenic Pathways in Hematologic Tumors In Vitro and In Vivo. Frontiers in Pharmacology, 2021, 12, 741697.	3.5	7
28	Discovery of new thienopyrimidine derivatives as potent and orally efficacious phosphoinositide 3-kinase inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 637-646.	3.0	5
29	The Development of a Biotinylated NAD+-Applied Human Poly(ADP-Ribose) Polymerase 3 (PARP3) Enzymatic Assay. SLAS Discovery, 2018, 23, 545-553.	2.7	4
30	A novel PI3K/mTOR dual inhibitor XH002 exhibited robust antitumor activity in NSCLC. Journal of Drug Targeting, 2019, 27, 451-459.	4.4	4
31	The PI3K Inhibitor XH30 Enhances Response to Temozolomide in Drug-Resistant Glioblastoma via the Noncanonical Hedgehog Signaling Pathway. Frontiers in Pharmacology, 2021, 12, 749242.	3.5	4
32	Re-engineering and synthesis of cytotoxic 2,3:7,8-di(alkylenedioxy)-extended analogs of quaternary sanguinarine chloride. Journal of Asian Natural Products Research, 2018, 20, 1137-1153.	1.4	2
33	Racemic 3,4-dihydro-4-naphthyl-naphthalen-1(2H)-ones from Juglans regia flowers. FÃ¬toterapÃ¬Ã¢, 2019, 139, 104401.	2.2	1